Clinical Trial Update: MVA-BN-RSV Vaccine Trial [Phase 3]

View source ↗

Summary

Phase 3 trial of Bavarian Nordic's MVA-BN-RSV vaccine was terminated, with results posted on 2024-10-31.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• MVA-BN-RSV vaccine (MVA-BN-RSV)

Snippet

Sponsor: Bavarian Nordic | Conditions: Respiratory Syncytial Virus Infections | Phase 3 | Status: TERMINATED | Results posted: 2024-10-31